Zymergen Investors Get First OK For $125M Settlement
Former executives, underwriters and large investors of now-defunct biotechnology company Zymergen received initial approval on Monday of a $125 million deal to end claims that they misled shareholders ahead of the...To view the full article, register now.
Already a subscriber? Click here to view full article